Uncategorized
RetroSense Therapeutics doses first patient in phase 1/2 clinical study of RST-001
The first patient has been dosed in a phase 1/2 clinical study of RST-001, a gene therapy designed to restore vision in patients with retinitis pigmentosa, according to a press release from RetroSense Therapeutics.In the first part of the study, three groups of patients will be administered three dose levels of RST-001 to determine a single dose that is safe and well-tolerated, which will be then administered to a fourth group of patients. The second part of the study will obtain additional safety data at the highest tolerated dose and (Read more...)